Printer Friendly

BTG BEGINS OSTEOARTHRITIS OF KNEE DRUG EFFICACY STUDY.

Bio-Technology General Corp. (NASDAQ:BTGC), Iselin. N.J., has initiated a safety and efficacy study of BioHy(TM), its high molecular weight sodium hyaluronate product, for the treatment of pain associated with osteoarthritis of the knee. The randomized, double blind study will compare BioHy with the current lead commercial product in the European viscoelastic market for osteoarthritis of the knee. The study, which is being conducted in Germany, will enroll 250 patients for a series of intra-articular injections of BioHy or the competitor's product into the knee, and is expected to be completed in the first half of 2000. Demonstration of comparable safety and efficacy of BioHy would lead to a regulatory submission for approval to market the product in Europe.

Injections of sodium hyaluronate into the knee have been shown to reduce pain associated with osteoarthritis of the knee by augmenting elastoviscosity within the joint. The current worldwide market for viscoelastic products for osteoarthritis of the knee is approximately $400 million, and is expected to grow as the aging population increases.

BTG's chairman and CEO, Sim Fass, stated: "The increasing elderly population is creating a greater need and larger market potential for viscoelastic products for osteoarthritis. We believe, therefore, that BioHy could have an important role to play in the market for such products."

Bio-Technology General Corp., a leading biopharmaceutical company, develops, manufactures and markets genetically engineered and other products for human health care. BTG's products are marketed in over thirty countries worldwide.

For more information, call 732-632-8800.
COPYRIGHT 1999 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1999 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Comment:BTG BEGINS OSTEOARTHRITIS OF KNEE DRUG EFFICACY STUDY.
Publication:Biotech Business
Geographic Code:1USA
Date:Oct 1, 1999
Words:249
Previous Article:FDA REQUESTS MODIFICATIONS TO BLA FOR BEXXAR.
Next Article:ARGOMED GETS FDA APPROVAL FOR TREATMENT OF BPH.
Topics:


Related Articles
Significant findings in recent glucosamine/chondroitin trials could boost sales growth.
Methylsulfonylmethane (MSM).

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters